What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?
Vor Biopharma Inc. (NASDAQ:VOR) announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed ...
C&EN18d
Thinking on linkers for antibody-drug conjugates
In the chemical world, the tiny hyphen in antibody-drug conjugates—or ADCs, as they’re commonly known—does a lot more work ...
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies
Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging ...
Vor Bio(VOR.US)基因编辑干细胞疗法获重要进展 股价盘后一度暴涨超70%
自上市以来股价跌跌不休的Vor Bio (VOR.US)似乎迎来“超级反转”，该公司股票价格在周四美股盘后交易中一度暴涨超70%，此前该公司报告了其基因编辑干细胞疗法 trem-cel 治疗急性髓性白血病 (AML) 的积极数据。基因编辑干细胞疗法trem-cel与 Mylotarg 联合治疗急性髓性白血病的1/2期试验数据积极，显示出联合疗效和药物安全性潜力。
这类技术正加速融入生产生活，有望催生万亿元市场增量
①这类技术正加速融入生产生活，有望催生万亿元市场增量;②三部门：在医疗领域开展扩大开放试点工作;③华为三折叠屏手机来了，行业逐步进入稳定增长期。 据报道，欧洲航天局位于国际空间站的金属3D打印机今年8月成功首次在太空微重力环境下打印出3D金属部件，有望在地-月、地-火任务中提供更多样的设备自定义能力。
9月6日美股盘前要闻
6、9月6日，法拉第未来 (FaradayFuture，FF)公告称，公司已从中东、美国和亚洲投资者处获得了3000万美元的融资承诺。同时，收到纳斯达克书面通知，确认公司重新满足了《纳斯达克上市规则》中的股价要求和定期申报要求，公司现已符合纳斯达克继续上市的所有标准。
PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies
PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies ...
Vor Biopharma: New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies
Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with signif ...